Navigation Links
Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study

Phase III trial planned
Abstracts: 2000, 2002

CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of a Phase I/IIa study presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago demonstrate the clinical activity of cilengitide in patients with newly diagnosed glioblastoma – a particularly aggressive form of brain tumor. Cilengitide is a highly selective integrin inhibitor targeting the tumor and its vasculature.

Fifty-two patients with newly diagnosed glioblastoma were treated with cilengitide, combined with a standard regimen of radiotherapy and temozolomide following tumor resection or biopsy. The study reached the predefined primary endpoint with 69% of patients being alive and progression free at six months, and showed a median progression free survival (PFS) of 8.1 months. In a defined patient subgroup with the methylated MGMT gene promoter in the tumor tissue, 91% of patients had six months PFS and the median has not yet been reached. These results are encouraging when compared to the historical control of the EORTC-NCIC phase III trial [overall population: 54% 6 months PFS, median PFS of 6.9 months;(1) methylated MGMT gene promoter subgroup: 69% PFS and 10.3 months median PFS].(2)

Lead investigator Dr. Roger Stupp of the University of Lausanne Hospital in Switzerland, commented: “We are excited by these findings. They demonstrate the potential of cilengitide to make a real difference to the outcome of patients with this aggressive type of brain cancer, where currently available treatment options are limited and prognosis is poor. We look forward to learning more about the benefits of this promising agent in larger patient populations.”

Also presented at ASCO was a Phase IIa randomized multicenter trial, examining two dosing levels of cilengitide monotherapy (500mg and 2000mg) in 81 patients with recurrent gliobl
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
11. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
Post Your Comments:
(Date:7/11/2014)... 11, 2014 Neurelis, Inc. ("Neurelis") today announced ... the option held by Biotie to purchase Neurelis, clearing ... NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients ... past year, Biotie has advanced the development program for ... pivotal clinical work required for NDA submission to the ...
(Date:7/10/2014)... 10, 2014  The U.S. Department of Health and ... University Hospitals (UH) Case Medical Center Seidman Cancer Center ... aimed at improving care for patients with complex cancer. ... will test a unique model developed at UH to ... significant comorbidities, or demonstrated need for high health care ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Corporation (NASDAQ: LMNX ) today announced ... at the Defense Threat Reduction Agency,s (DTRA) 2011 ... Conference, which takes place November 14-16, 2011 in ... During the conference, Dr. Altman will present ...
... 14, 2011 HeartSine® Technologies, Inc., a world leader ... of a new global website at www.heartsine.com . ... across the globe and is committed to providing innovative, ... sudden cardiac death. HeartSine Automated ...
Cached Medicine Technology:Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 2Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 3HeartSine® Technologies Launches New Global Website 2
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... July 12, 2014 Sean Francis, owner of the ... special challenges to his clients. He’s also known for his support ... found a way to combine the two and is excited to ... for the Boys and Girls Club. , The funds are the ... on June 23rd. Francis sent out emails and asked his clients ...
(Date:7/12/2014)... 12, 2014 For those who are unfamiliar ... readily absorb the nutrients in food. The enzymes literally break ... small enough to be absorbed by human bodies. According Dr. ... of enzymes in regular food is the cause of many ... was started by Michelle DelPresto, a mother of 3 who ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... Restore My Vision Today is a new product ... boasting very impressive credentials on the field of ophthalmology. ... a way to help consumers do without the “middleman ... respective patients’ treatments . , In particular, the ... pertinent information relevant to eye care like:, ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... medical researchers in the United States has discovered what may ... cancer.// ,The scientists from the University of ... halting the activity of a single enzyme called aldose reductase. ... of biochemical signals that promotes inflammation and colon cancer cell ...
... of interest for post menopausal women with breast cancer ... Herceptin (trastuzumab) from Roche// and Arimidex (anastrozole) from AstraZeneca ... time by 4.8 months. ,A Phase III clinical ... the progression by just 2.4 months after which the ...
... people affected by chikungunya, a viral fever caused by mosquitoes//, ... the state government on the nature of the disease. ... not chikungunya. The government is doing its best to contain ... have asked people from other systems of medicines like Ayurveda ...
... an undiagnosed disorder and fighting to stay in Canada, has ... state after three years.// ,"I just hugged them... and ... parents landed at Vancouver airport last week. ,Dhaval ... Gujarat advised him to move after looking at his condition ...
... It was just weeks following the 9/11 attacks in ... offices of the news media and two US senators//. The ... five people and infected 17 others. , ,In a ... University of Georgia, teaming up with scientists at the federal ...
... and at times even forbid birthday cupcakes due to ... bring carrots," said Laura Ott, assistant to the superintendent.,A ... a sticker and a pencil instead of sweets from ... Unified School District, in Orange County, Calif., has restricted ...
Cached Medicine News:Health News:Indian with Rare Disorder Reunited with Family 2Health News:Cell-Wall Carbohydrate in Anthrax Bacterium Holds Promise for New Vaccines 2
... innovative, quick and easy automated refill ... less space on your laboratory bench ... amazingly easy-to-use, one-hand system, you only ... range of Diamond Tips. All sizes ...
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes....
... use: when presented in convenient, steady, ... to pick up directly from the ... 96 tips are loaded without manual ... a security sticker. Fully autoclavable, Tipacks ...
... is an innovative, quick and easy ... Use 60% less space on your ... With this amazingly easy-to-use, one-hand system, ... the whole range of Diamond Tips. ...
Medicine Products: